• Pharma Intelligence

Datamonitor Healthcare estimates that Parkinson’s disease sales will grow substantially in the US, Japan, and five major EU markets, expanding from $3.2bn in 2016 to $6.0bn in 2025. Growth will be driven by the aging of the susceptible elderly population, US drug price inflation, and uptake of new late-stage treatment options.
Read more...